BioInformant

Your Global Leader in Stem Cell Market Research

Home » NiCord

Gamida Cell, President Dr. Yael Margolin Reveals the Unmet Need in HSCT

By

Dr. Yael Margolin, CEO of Gamida Cell
Dr. Yael Margolin, President of Gamida Cell

Gamida Cell is a cell therapy company that is best known for its innovative approaches to hematopoietic stem cell transplantation (HSCT). Headquartered in Jerusalem, Israel, Gamida Cell has been advancing several clinical programs using ex vivo expanded hematopoietic stem cells (HSCs) created using its proprietary nicotinamide (NAM) technology.

I had the honor of interviewing Dr. Yael Margolin, President of Gamida Cell. In this interview, we discuss how Gamida Cell is using cell therapeutics to address the unmet need in hematopoietic stem cell transplantation (HSCT). [Read more…]

Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?

By

Gamida CellGamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.

NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]

Gamida Cell Announces $40 Million Private Financing

By

Financing provides strong base to complete Phase 3 clinical trial and commercialization of lead product candidate NiCord® for blood cancers

Gamida CellJerusalem, Israel, June 19, 2017 — Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the signing of a $40 million financing to support the ongoing Phase 3 trial of the Company’s FDA Breakthrough Designated clinical-stage product, NiCord, to facilitate bone marrow transplantation. The financing is being led by new investor Shavit Capital. Additional primary participants include new investors VMS Investment Group and Israel Biotech Fund, as well as existing investor and major shareholder, Novartis. Current shareholders Clal Biotechnology Industries (CBI) and Israel HealthCare Ventures (IHCV) also participated in the financing.

“We are very pleased to have the strong support from both new and current investors as we continue to advance our lead product NiCord through late stage development and toward commercialization,” said Gamida Cell President and CEO Yael Margolin, Ph.D. “With this financing, we are well-positioned to complete the Phase 3 clinical trial of NiCord with the goal of bringing this lead product candidate to market and filling an important unmet need in bone marrow transplantation for blood cancer patients who cannot rapidly find a fully matched donor.” [Read more…]

Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

By

Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments

Ronit Simantov, Chief Medical Officer of Gamida Cell
Ronit Simantov, Chief Medical Officer of Gamida Cell

Jerusalem, Israel and New York, New York,  July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join the Company as its new Chief Medical Officer (CMO) based in the U.S. [Read more…]

Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in HSCT

By

Phase 3 study of NiCord commenced last month in blood cancer patients

Jerusalem, Israel, March 23, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that orphan drug designation has been granted by the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) regarding NiCord® as a treatment for haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation (BMT).

“We are very encouraged that the EMA has widened NiCord’s orphan drug designation to include BMT, and believe it is an important recognition of the unmet needs in these indications,” said Gamida Cell president and CEO Dr. Yael Margolin. “This broadened regulatory designation adds a key layer of market exclusivity for NiCord as we move forward with our Phase 3 study and prepare for commercialization.” [Read more…]

BioInformant's World-Class Clients